CILAZAPRIL

Cilazapril is an ACE inhibitor reducing angiotensin II formation to lower blood pressure. Benefits include improved cardiac outcomes. Side effects include cough, dizziness, and hyperkalemia.

SKU: 2a8539bef9c8 Category: Tag:

Product Description


Mechanism of Action

Cilazapril is an angiotensin‑converting enzyme (ACE) inhibitor administered as a prodrug converted to cilazaprilat. It inhibits ACE‑mediated conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion and sympathetic tone. This lowers systemic vascular resistance and improves endothelial function.

Benefits and Advantages

Used in RAAS‑pathway research, cardiovascular‑remodelling studies, hypertension models, endothelial‑function experiments and ACE‑inhibitor SAR investigations.

Side Effects and Risks

Risks include cough, hyperkalemia, hypotension, renal impairment, angioedema and fetal toxicity. Handle as a potent RAAS‑modulating compound.

Datasheet


Molecular Formula

C22H24N2O5

Molecular Weight

417.5 g/mol

CAS Number

88768-40-5

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Water (25 ºC) 0.5 g/100 mL

Purity

Purity information is available upon request (COA).

Synonym

cilazapril; 88768-40-5; Inhibace; Cilazapril anhydrous; Cilazaprilum

IUPAC/Chemical Name

(4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid

InChl Key

HHHKFGXWKKUNCY-FHWLQOOXSA-N

InChl Code

InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1

References

PubChem; ChemBL; FDA;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download